Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Global Osteoarthritis Market 2016 Share, Trend, Segmentation and Forecast to 2022

Monday, October 10, 2016 3:38
% of readers think this story is Fact. Add your two cents.

(Before It's News)


Global Markets Direct’s, ‘Osteoarthritis – Pipeline Review, H2 2016’, provides an overview of the Osteoarthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteoarthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects.

Complete report details @

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


- The report provides a snapshot of the global therapeutic landscape of Osteoarthritis 
- The report reviews pipeline therapeutics for Osteoarthritis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Osteoarthritis therapeutics and enlists all their major and minor projects
- The report assesses Osteoarthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Osteoarthritis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Osteoarthritis 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Osteoarthritis pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Request a sample report @

Key points in table of content

Table of Contents 
Table of Contents 2 
Introduction 6 
Osteoarthritis Overview 7 
Therapeutics Development 8 
Osteoarthritis – Therapeutics under Development by Companies 10 
Osteoarthritis – Therapeutics under Investigation by Universities/Institutes 15 
Osteoarthritis – Pipeline Products Glance 16 
Osteoarthritis – Products under Development by Companies 19 
Osteoarthritis – Products under Investigation by Universities/Institutes 25 
Osteoarthritis – Companies Involved in Therapeutics Development 26 
Osteoarthritis – Therapeutics Assessment 82 
Drug Profiles 96 
Osteoarthritis – Dormant Projects 244 
Osteoarthritis – Discontinued Products 254 
Osteoarthritis – Product Development Milestones 256 
Appendix 268

List of Tables 

Number of Products under Development for Osteoarthritis, H2 2016 20 
Number of Products under Development for Osteoarthritis – Comparative Analysis, H2 2016 21 
Number of Products under Development by Companies, H2 2016 22 
Number of Products under Development by Companies, H2 2016 (Contd..1) 23 
Number of Products under Development by Companies, H2 2016 (Contd..2) 24 
Number of Products under Development by Companies, H2 2016 (Contd..3) 25 
Number of Products under Development by Companies, H2 2016 (Contd..4) 26 
Number of Products under Investigation by Universities/Institutes, H2 2016 27 
Comparative Analysis by Late Stage Development, H2 2016 28 
Comparative Analysis by Clinical Stage Development, H2 2016 29 
Comparative Analysis by Early Stage Development, H2 2016 30 
Products under Development by Companies, H2 2016 31 
Products under Development by Companies, H2 2016 (Contd..1) 32 
Products under Development by Companies, H2 2016 (Contd..2) 33 
Products under Development by Companies, H2 2016 (Contd..3) 34 
Products under Development by Companies, H2 2016 (Contd..4) 35 
Products under Development by Companies, H2 2016 (Contd..5) 36 
Products under Investigation by Universities/Institutes, H2 2016 37 

Make an enquiry before buying this Report @

Osteoarthritis – Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2016 38 
Osteoarthritis – Pipeline by AbbVie Inc, H2 2016 39 
Osteoarthritis – Pipeline by Abiogen Pharma S.p.A., H2 2016 40 
Osteoarthritis – Pipeline by Ablynx NV, H2 2016 41 
Osteoarthritis – Pipeline by Achelios Therapeutics, Inc., H2 2016 42 
Osteoarthritis – Pipeline by Addex Therapeutics Ltd, H2 2016 43 
Osteoarthritis – Pipeline by Amgen Inc., H2 2016 44 
Osteoarthritis – Pipeline by Amura Holdings Limited, H2 2016 45 
Osteoarthritis – Pipeline by Arcarios BV, H2 2016 46 
Osteoarthritis – Pipeline by Asahi Kasei Pharma Corp., H2 2016 47 
Osteoarthritis – Pipeline by Asklepios BioPharmaceutical, Inc., H2 2016 48 
Osteoarthritis – Pipeline by Astellas Pharma Inc., H2 2016 49 
Osteoarthritis – Pipeline by Asterias Biotherapeutics, Inc., H2 2016 50 
Osteoarthritis – Pipeline by Biopharm GmbH, H2 2016 51 
Osteoarthritis – Pipeline by Bone Therapeutics SA, H2 2016 52 
Osteoarthritis – Pipeline by Can-Fite BioPharma Ltd., H2 2016 53 
Osteoarthritis – Pipeline by Cardax Pharmaceuticals, Inc., H2 2016 54 
Osteoarthritis – Pipeline by Cellceutix Corporation, H2 2016 55 
Osteoarthritis – Pipeline by Cellular Biomedicine Group, Inc., H2 2016 56 
Osteoarthritis – Pipeline by Evgen Pharma Plc, H2 2016 57 
Osteoarthritis – Pipeline by Galapagos NV, H2 2016 58 
Osteoarthritis – Pipeline by Genequine Biotherapeutics GmbH, H2 2016 59 
Osteoarthritis – Pipeline by GlaxoSmithKline Plc, H2 2016 60 
Osteoarthritis – Pipeline by IntelliCell BioSciences Inc., H2 2016 61 
Osteoarthritis – Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016 62 
Osteoarthritis – Pipeline by Jenrin Discovery, Inc., H2 2016 63 
Osteoarthritis – Pipeline by K-Stemcell Co., Ltd., H2 2016 64 
Osteoarthritis – Pipeline by Levolta Pharmaceuticals, Inc., H2 2016 65 
Osteoarthritis – Pipeline by Medivir AB, H2 2016 66 
Osteoarthritis – Pipeline by Merck KGaA, H2 2016 67 
Osteoarthritis – Pipeline by Mesoblast Limited, H2 2016 68 
Osteoarthritis – Pipeline by Mor Research Application Ltd, H2 2016 69 
Osteoarthritis – Pipeline by NicOx S.A., H2 2016 70 
Osteoarthritis – Pipeline by Nordic Bioscience A/S, H2 2016 71 
Osteoarthritis – Pipeline by Novartis AG, H2 2016 72 
Osteoarthritis – Pipeline by Omeros Corporation, H2 2016 73 
Osteoarthritis – Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 74 
Osteoarthritis – Pipeline by OrthoCyte Corporation, H2 2016 75 
Osteoarthritis – Pipeline by Osteologix Holdings Plc., H2 2016 76 
Osteoarthritis – Pipeline by Pfizer Inc., H2 2016 77 
Osteoarthritis – Pipeline by Pharmalink AB, H2 2016 78 
Osteoarthritis – Pipeline by Philogen S.p.A., H2 2016 79 
Osteoarthritis – Pipeline by PLx Pharma Inc., H2 2016 80 
Osteoarthritis – Pipeline by ProteoThera, Inc., H2 2016 81 
Osteoarthritis – Pipeline by Regeneus Ltd, H2 2016 82 
Osteoarthritis – Pipeline by Seikagaku Corporation, H2 2016 83 
Osteoarthritis – Pipeline by STELIS Biopharma Pvt. Ltd., H2 2016 84 
Osteoarthritis – Pipeline by Symic Biomedical, Inc., H2 2016 85 
Osteoarthritis – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 86 
Osteoarthritis – Pipeline by TissueGene, Inc., H2 2016 87 
Osteoarthritis – Pipeline by Upsher-Smith Laboratories, Inc., H2 2016 88 
Osteoarthritis – Pipeline by Yooyoung Pharmaceutical Co., Ltd., H2 2016 89 
Osteoarthritis – Pipeline by Yuhan Corporation, H2 2016 90 
Osteoarthritis – Pipeline by Yungjin Pharm. Co., Ltd., H2 2016 91 
Osteoarthritis – Pipeline by Zimmer Biomet Holdings, Inc., H2 2016 92 
Osteoarthritis – Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016 93 
Assessment by Monotherapy Products, H2 2016 94 
Assessment by Combination Products, H2 2016 95 
Number of Products by Stage and Target, H2 2016 97 
Number of Products by Stage and Mechanism of Action, H2 2016 101 
Number of Products by Stage and Route of Administration, H2 2016 105 
Number of Products by Stage and Molecule Type, H2 2016 107 
Osteoarthritis – Dormant Projects, H2 2016 256 
Osteoarthritis – Dormant Projects (Contd..1), H2 2016 257 
Osteoarthritis – Dormant Projects (Contd..2), H2 2016 258 
Osteoarthritis – Dormant Projects (Contd..3), H2 2016 259 
Osteoarthritis – Dormant Projects (Contd..4), H2 2016 260 
Osteoarthritis – Dormant Projects (Contd..5), H2 2016 261 
Osteoarthritis – Dormant Projects (Contd..6), H2 2016 262 
Osteoarthritis – Dormant Projects (Contd..7), H2 2016 263 
Osteoarthritis – Dormant Projects (Contd..8), H2 2016 264 
Osteoarthritis – Dormant Projects (Contd..9), H2 2016 265 
Osteoarthritis – Discontinued Products, H2 2016 266 
Osteoarthritis – Discontinued Products (Contd..1), H2 2016 267

Get this report @

Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.